| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 01/29/2003 | EP1278778A2 Modified peptides, comprising an fc domain, as therapeutic agents |
| 01/29/2003 | EP1278777A2 G protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same |
| 01/29/2003 | EP1278774A2 Human g-protein coupled receptors |
| 01/29/2003 | EP1278772A2 Glucagon antagonists |
| 01/29/2003 | EP1278767A1 Albumin fusion proteins |
| 01/29/2003 | EP1278751A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists |
| 01/29/2003 | EP1278750A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives |
| 01/29/2003 | EP1278749A1 USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 01/29/2003 | EP1278748A2 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/29/2003 | EP1278739A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor |
| 01/29/2003 | EP1278732A1 1-aroyl-piperidinyl benzamidines |
| 01/29/2003 | EP1278729A1 Benzosuberonylpiperidine compounds as analgesics |
| 01/29/2003 | EP1278723A2 P-(sulfonyl)-aryl and -heteroaryl amines |
| 01/29/2003 | EP1278719A1 Naphthamide neurokinin antagonists for use as medicaments |
| 01/29/2003 | EP1278716A1 Cyclohexylamine derivative as subtype selective nmda receptor antagonists |
| 01/29/2003 | EP1278544A2 Albumin fusion proteins |
| 01/29/2003 | EP1278543A2 Antibody binding alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 01/29/2003 | EP1278540A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 01/29/2003 | EP1278528A1 Nucleoside analogs with carboxamidine-modified bicyclic base |
| 01/29/2003 | EP1278513A2 A core formulation |
| 01/29/2003 | EP1278502A2 Protease inhibitors |
| 01/29/2003 | EP1161434B1 Pyridopyranoazepine derivatives, preparation and therapeutic use |
| 01/29/2003 | EP1028948B1 Phenyl-alkyl-imidazoles as h3 receptor antagonists |
| 01/29/2003 | EP0832081B1 Bicyclic-aromatic compounds |
| 01/29/2003 | EP0546007B2 Product and use of it for the treatment of catabolic states comprising authentic igf-1 and hypocaloric amount of nutritients |
| 01/29/2003 | CN1394206A Novel vitamin D analogues |
| 01/29/2003 | CN1394201A Substituted glutarimides and use thereof IL-12 production inhibitors |
| 01/29/2003 | CN1394142A Use of cyclic ether for preparation of medicaments affecting glucose tolerance |
| 01/29/2003 | CN1393546A Industrial fermenting process of sphaeroid red bacteria and its fermented liquid |
| 01/29/2003 | CN1393265A Method for reducing fasting blood-glucose of diabetic and weight |
| 01/29/2003 | CN1393264A Application of herberine as sensibilizer of insulin |
| 01/29/2003 | CN1393241A Onion extract and its preparing process |
| 01/29/2003 | CN1393226A Lotus-root cellulose tablet for treating obesity |
| 01/29/2003 | CN1393174A Pumpkin milk tea |
| 01/29/2003 | CN1099882C Medicine for reducing weight and its making method |
| 01/29/2003 | CN1099841C Application of phospholipases in animal feed |
| 01/29/2003 | CN1099835C Antilipemic beverage or tea |
| 01/28/2003 | WO2002009757A1 Preventives or remedies for obesity or fatty liver |
| 01/28/2003 | US6512099 Roselipin derivative |
| 01/28/2003 | US6512001 D-proline derivatives |
| 01/28/2003 | US6511997 For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease |
| 01/28/2003 | US6511985 HMG-CoA reductase inhibitor cerivastatin with fibrates such as fenofibrate or bezafibrate for the treatment of disorders of lipid metabolism |
| 01/28/2003 | US6511984 Neuropeptide Y antagonists |
| 01/28/2003 | US6511981 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 01/28/2003 | US6511980 For therapy of gastrointestinal reflux disorders, eating disorders leading to obesity and irritable bowel disorder |
| 01/28/2003 | US6511966 Administering for therapy of mitochondria medited disease |
| 01/28/2003 | US6511811 Protein kinase C antagonist related to insulin receptor |
| 01/28/2003 | US6511807 Carbohydrate ligand that specifically binds to a leczyme; nucleic acid sequence encoding a nonclassical MHC class I heavy chain; ability to associate with a beta 2 microglobulin; major histocompatibility complex transplantation molecules |
| 01/28/2003 | US6511685 Heating in presence of bacteria then yeast; adding calcium, magnesium and/or potassium components; filtering and drying |
| 01/28/2003 | US6511675 Dietary supplements |
| 01/28/2003 | CA2417492A1 Preventives or remedies for obesity or fatty liver |
| 01/28/2003 | CA2127553C Peptides with organo-protective activity, process for their preparation and their use in the therapy |
| 01/28/2003 | CA2033469C Composition and method for the treatment of osteoporosis in mammals |
| 01/27/2003 | CA2391216A1 Identification and use of molecules implicated in pain |
| 01/23/2003 | WO2003006996A2 Natural ligand of gpcr chemr23 and uses thereof |
| 01/23/2003 | WO2003006893A2 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | WO2003006661A2 Transgenic plants expressing cobalamin binding proteins |
| 01/23/2003 | WO2003006645A2 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | WO2003006620A2 Linear and cyclic melanocortin receptor-specific peptides |
| 01/23/2003 | WO2003006608A2 Enhancement of transfection of dna into the liver |
| 01/23/2003 | WO2003006604A2 Cyclic peptides as potent and selective melanocortin-4 receptor agonists |
| 01/23/2003 | WO2003006492A2 Biologically active peptides |
| 01/23/2003 | WO2003006478A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | WO2003006477A1 IN VIVO PRODUCTION OF SMALL INTERFERING RNAs THAT MEDIATE GENE SILENCING |
| 01/23/2003 | WO2003006466A1 Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands |
| 01/23/2003 | WO2003006459A1 Piperazine oxime derivatives having nk-1 receptor antagonistic activity |
| 01/23/2003 | WO2003006438A1 Benzimidazole derivatives for treating microglia-activation associated diseases such as inflammatory, allergic, infectious or autoimmune diseases |
| 01/23/2003 | WO2003006051A1 Use of corticotroph-derived glycoprotein hormone to induce lipolysis |
| 01/23/2003 | WO2003006022A1 Tetrahydroquinoline derivatives and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 01/23/2003 | WO2003006010A1 Aerosol formulations of δ8 tetrahydrocannabinol |
| 01/23/2003 | WO2003006004A2 Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
| 01/23/2003 | WO2003006003A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 01/23/2003 | WO2003006002A1 Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 01/23/2003 | WO2003005998A2 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function |
| 01/23/2003 | WO2003005995A1 Core formulation comprising pioglitazone hydrochloride and a biguanide |
| 01/23/2003 | WO2003005991A1 A core formulation |
| 01/23/2003 | WO2003005971A2 Tetracycline compounds having target therapeutic activities |
| 01/23/2003 | WO2003005962A2 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate |
| 01/23/2003 | WO2003005959A2 Amphiphilic star-like macromolecules for drug delivery |
| 01/23/2003 | WO2003005837A1 Enteral formulations |
| 01/23/2003 | WO2003005819A1 Use of cross-linked, covalently bound urokinase plasminogen activator (scupa)-urokinase plasminogen activator receptor (supar) complex as a fibrinolytic agent |
| 01/23/2003 | WO2002088143A3 Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands |
| 01/23/2003 | WO2002083159B1 Palliative effects of morinda citrifolia oil and juice |
| 01/23/2003 | WO2002072114A3 Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent |
| 01/23/2003 | WO2002070676A3 Use of protein histidine phosphatase |
| 01/23/2003 | WO2002066978A3 Detection of compounds that modulate inflammatory responses |
| 01/23/2003 | WO2002066509A3 Treatment involving dkk-1 or antagonists thereof |
| 01/23/2003 | WO2002055152A9 Composition for inducing islet neogenesis, containing gastrin/cck receptor ligands and egf receptor ligands |
| 01/23/2003 | WO2002050066A3 Pyrazole compounds useful as protein kinase inhibitors |
| 01/23/2003 | WO2002047456A3 Urotensin-ii receptor antagonists |
| 01/23/2003 | WO2002046171A3 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto |
| 01/23/2003 | WO2002046138A3 Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| 01/23/2003 | WO2002043662A3 Dietary composition containing conjugated linoleic acid and calcium for improved health |
| 01/23/2003 | WO2002041835A3 Estrogen receptor modulators |
| 01/23/2003 | WO2002036741A3 Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme |
| 01/23/2003 | WO2002033095A3 Regulation of human serine-threonine protein kinase |
| 01/23/2003 | WO2002020619A3 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 01/23/2003 | WO2002013798A3 Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors |
| 01/23/2003 | WO2002010363A3 Protein phosphatases |
| 01/23/2003 | WO2001083782A3 Novel proteases |